CPHI
AMEX · Pharmaceuticals
China Pharma Holdings Inc
$0.53
+0.00 (+0.75%)
Financial Highlights (FY 2026)
Revenue
39.74M
Net Income
-30,569,684
Gross Margin
-3.2%
Profit Margin
-76.9%
Rev Growth
-20.0%
D/E Ratio
0.15
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | -3.2% | -3.2% | 44.6% | 44.6% |
| Operating Margin | -78.2% | -70.3% | 15.6% | 17.1% |
| Profit Margin | -76.9% | -73.1% | 12.8% | 15.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 39.74M | 49.70M | 1.71M | 1.69M |
| Gross Profit | -1,263,829 | -1,580,378 | 763.3K | 752.6K |
| Operating Income | -31,063,174 | -34,959,180 | 266.9K | 288.3K |
| Net Income | -30,569,684 | -34,403,795 | 218.9K | 263.0K |
| Gross Margin | -3.2% | -3.2% | 44.6% | 44.6% |
| Operating Margin | -78.2% | -70.3% | 15.6% | 17.1% |
| Profit Margin | -76.9% | -73.1% | 12.8% | 15.6% |
| Rev Growth | -20.0% | -20.0% | -8.6% | -6.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.38M | 1.38M | 1.64M | 1.66M |
| Total Equity | 9.17M | 9.17M | 2.45M | 2.52M |
| D/E Ratio | 0.15 | 0.15 | 0.67 | 0.66 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -21,441,580 | -25,471,428 | 383.8K | 387.9K |
| Free Cash Flow | — | — | 127.8K | 154.0K |